Evidence map›Paper›PMID 27592294›Full record

Observational studyAmerican journal of nephrology2016

Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes.

Nishank Jain, Thomas Carmody, Abu T Minhajuddin, Marisa Toups, Madhukar H Trivedi, Augustus John Rush, S Susan Hedayati

Abstract readComparative StudyObservational Study
In one paragraph

Observational study in American journal of nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Nishank JainDivision of Nephrology, Department of Internal Medicine, University of Arkansas Medical Center, Little Rock, Ark., USA.
Thomas Carmody
Abu T Minhajuddin
Marisa Toups
Madhukar H Trivedi
Augustus John Rush
S Susan Hedayati
Cancer Research And Biostatistics · USDuke-NUS Medical School · SGThe University of Texas Southwestern Medical Center · USUniversity of Arkansas Medical Center · US

Funding

Randomized trial of sertraline treatment of depression in Chronic Kidney DiseaseR01DK085512 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HEDAYATI, SUSAN · 2011 to 2015
$1.8M
Randomized trial of sertraline treatment of depression in Chronic Kidney DiseaseI01CX000217 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · PI HEDAYATI, SUSAN · 2009 to 2012
–
CSRD VA I01 CX000217NIDDK NIH HHS R01 DK085512
6 · The paper itself

Abstract

backgroundThe prognostic utility of self-administered depression scales in chronic kidney disease (CKD) independent of a clinician-based major depressive disorder (MDD) diagnosis is neither clearly established nor are the optimal cutoff scores for predicting outcomes. The overlap between symptoms of depression and chronic disease raises the question of whether a cutoff score on a depression scale can be substituted for a time-consuming diagnostic interview to prognosticate risk.

methodsThe 16-item Quick Inventory of Depression Symptomatology-Self Report scale (QIDS-SR16) was administered to 266 consecutive outpatients with non-dialysis CKD, followed prospectively for 12 months for an apriori composite outcome of death or dialysis or hospitalization. Association of QIDS-SR16 best cutoff score, determined by receiver/responder operating characteristics curves, with outcomes was investigated using survival analysis. The effect modification of an interview-based clinician MDD diagnosis on this association was ascertained.

resultsThere were 126 composite events. A QIDS-SR16 cutoff ≥8 had the best prognostic accuracy, hazards ratio (HR) = 1.77, 95% CI 1.24-2.53, p = 0.002. This cutoff remained significantly associated with outcomes even after controlling for comorbidities, estimated glomerular filtration rate, hemoglobin and serum albumin, adjusted HR (aHR) = 1.80, 95% CI 1.23-2.62, p = 0.002, and performed similarly to a clinician-based MDD diagnosis (aHR = 1.72, 95% CI 1.14-2.68). Adjustment for MDD conferred the association of QIDS-SR16 with outcomes no longer significant.

conclusionsQIDS-SR16 cutoff ≥8 adds to the prognostic information available to practicing nephrologists during routine clinic visits from comorbidities and laboratory data. This cutoff score performs similar to a clinician diagnosis of MDD and provides a feasible and time-saving alternative to an interview-based MDD diagnosis for determining prognosis in CKD patients.

Indexed as

Psychiatric Status Rating ScalesSelf ReportAdultAgedAged, 80 and overDisease ProgressionFemaleHospitalizationHumansMajor Depressive DisorderMaleMiddle AgedPrognosisProportional Hazards ModelsProspective StudiesRenal Dialysis

Identifiers

PMID27592294
PMCPMC5033719
OpenAlexW2510516971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.